Gabather was founded in 2014, based on 10 years research at Lund University, to develop new small molecule drug candidates for the treatment of CNS diseases by targeting one of the main inhibitory neurotransmitter system in the brain, GABA (gamma-amino butyric acid). Gabather was founded by Forskarpatent I Syd AB and inventors Olov Sterner and Mogens Nielsen, both of whom enjoy world-wide renown and are highly regarded within their areas. The owners of Gabather include the inventors, as well as Forskarpatent I Syd AB along with other shareholders.
During your time at the company, what has been in your eyes your greatest achievement thus far?
The team’s greatest achievement-so far- has been the submission of the clinical trial application, marking the transition from preclinic to clinic-a huge step for a small biotech company working in drug discovery and development.
What is your medium to long-term goals and have these goals been consistent for some time?
Our medium to long-term goals have always been to establish ourselves as a drug discovery and development company focusing on diseases of the central nervous system targeting the neurotransmitter GABA as a drug target. We want to fill the large unmet medical need by developing efficacious and safe therapies for the ultimate stakeholder in this process: the patient
What sets your company apart from those within your industry? Whats your X-factor per say?
I have worked in the field of drug discovery both in a startup, medium size as well as big pharma companies for 20 years and must say that this is the most knowledgeable, dedicated and enthusiastic team I have worked with. We have ultrashort and very efficient decision pathways and are very, very good at troubleshooting. Initiative-taking is automatic and micromanagement non-existent. I often get the question at the end of a conversation: ”……..and how many people did you say work at Gabather…?
Could you please share with us your favourite memory and or event since you joined the company?
My favorite moment was hearing the doorbell ring at the office with a parcel containing our clinical trial material being delivered: finally we had a product ! I still have that jar on my desk – a reminder of the ultimate goal of our projects: better medicines.